Omeros Corporation (NASDAQ:OMER - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $18.00.
Several research analysts have recently weighed in on OMER shares. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Omeros in a report on Friday, June 27th. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Friday, August 15th. Finally, Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th.
Read Our Latest Report on Omeros
Institutional Trading of Omeros
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros in the second quarter valued at approximately $32,000. Harbour Investments Inc. increased its position in shares of Omeros by 46.1% during the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 4,251 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 11,971 shares during the period. Sei Investments Co. purchased a new stake in shares of Omeros during the second quarter worth $40,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 1,972 shares during the period. Hedge funds and other institutional investors own 48.79% of the company's stock.
Omeros Stock Performance
Shares of Omeros stock traded down $0.21 on Friday, hitting $4.08. The company's stock had a trading volume of 466,908 shares, compared to its average volume of 907,110. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60. The firm has a fifty day moving average price of $3.80 and a 200-day moving average price of $5.39. The company has a market capitalization of $277.96 million, a price-to-earnings ratio of -1.94 and a beta of 2.37.
Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. As a group, analysts forecast that Omeros will post -3.09 EPS for the current year.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
